文献速递头颈部肿瘤放疗

头颈癌放疗后口干症的剂量-体积预测因素:系统综述

Dose-volume predictors of post-radiation xerostomia in head and neck cancer: A systematic review.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-09-06

该系统综述纳入51项研究共10789例接受根治性放疗的头颈癌患者,多数接受调强放疗。对侧腮腺平均剂量是口干症最一致验证的预测因素,证据确定性中等;对侧腮腺Dmean超过24-26 Gy时中重度口干症风险增加,低于20 Gy与更好的唾液保存相关。颌下腺和口腔的剂量学参数也独立关联口干症风险。

要点

  • 对侧腮腺平均剂量是放疗后口干症最稳健的预测因素,证据确定性中等。
  • 对侧腮腺Dmean超过24-26 Gy与中重度口干症风险增加相关,低于20 Gy与更好的唾液保存相关。
  • 颌下腺和口腔的剂量学参数也独立关联口干症风险,腮腺亚结构可能发挥作用。

核心结论

  • 腮腺平均剂量仍是头颈癌放疗后口干症最稳健的预测因素。
  • 颌下腺、口腔及腮腺亚结构的额外剂量学信息可能改善口干症风险分层并支持未来NTCP建模。

研究设计与样本

  • 基于PRISMA的系统综述,已在PROSPERO注册(CRD42024519338)。
  • 检索PubMed、Embase、Cochrane Library和Web of Science,纳入2013年1月至2025年8月发表的研究。
  • 纳入评估成人头颈癌根治性放疗患者口干症剂量-体积预测因素的研究。
  • 共纳入51项研究,涉及10789例患者,多数接受调强放疗。

主要发现

  • 对侧腮腺平均剂量是最一致验证的口干症预测因素,证据确定性中等。
  • 多项研究报告对侧腮腺Dmean超过24-26 Gy时中重度口干症风险增加,低于20 Gy与更好的唾液保存相关。
  • 也有报告双侧腮腺Dmean约26 Gy。
  • 颌下腺和口腔的剂量学参数也独立关联口干症风险。
  • 新兴证据提示腮腺亚结构(包括导管和干细胞富集区域)可能发挥作用。

关键数值与推荐

  • 对侧腮腺Dmean超过24-26 Gy与中重度口干症风险增加相关。
  • 对侧腮腺Dmean低于20 Gy与更好的唾液保存相关。
  • 双侧腮腺Dmean约26 Gy亦有报告。
  • 特定数值计划阈值的支持仍有限。

临床怎么用

  • 临床计划时应重点关注对侧腮腺平均剂量,尽量使其低于20 Gy以更好保存唾液功能。
  • 除腮腺外,可同时参考颌下腺和口腔的剂量学参数以综合评估口干症风险。
  • 腮腺亚结构(如导管和干细胞富集区域)的剂量信息可能有助于进一步风险分层。

局限性

  • 特定数值计划阈值的支持仍然有限。
  • 腮腺亚结构作用的证据尚属新兴,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Radiation-induced xerostomia remains a major toxicity after radiotherapy for head and neck cancer (HNC). Although QUANTEC-based parotid dose constraints are widely applied, increasing evidence suggests that additional salivary and oral structures may contribute to xerostomia risk. This systematic review aimed to summarize contemporary evidence on dose-volume predictors of post-radiotherapy xerostomia in HNC. MATERIALS AND METHODS: This PRISMA-based systematic review was registered in PROSPERO (CRD42024519338). PubMed, Embase, Cochrane Library, and Web of Science were searched for studies published between January 2013 and August 2025. Studies evaluating dose-volume predictors of xerostomia in adult HNC patients treated with curative-intent radiotherapy were included. RESULTS: Fifty-one studies involving 10,789 patients were included. Most patients received intensity-modulated radiotherapy. Contralateral parotid gland mean dose (Dmean) was the most consistently validated predictor of xerostomia and was supported by moderate-certainty evidence. Multiple studies reported increased risk of moderate-to-severe xerostomia when contralateral parotid Dmean exceeded 24-26 Gy, whereas Dmean below 20 Gy was associated with better salivary preservation. Bilateral parotid Dmean around 26 Gy was also reported. However, support for specific numerical planning thresholds remained limited. Dosimetric parameters of the submandibular glands and oral cavity were also independently associated with xerostomia risk. Emerging evidence suggested potential roles of parotid substructures, including ducts and stem cell-rich regions. CONCLUSION: Parotid gland mean dose remains the most robust predictor of post-radiotherapy xerostomia in HNC. Additional dosimetric information from the submandibular glands, oral cavity, and parotid substructures may further improve xerostomia risk stratification and support future NTCP modeling.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou J, Hou X, Liang W, et al. Dose-volume predictors of post-radiation xerostomia in head and neck cancer: A systematic review. Clin Transl Radiat Oncol. 2026. PMID: 42751136. doi:10.1016/j.ctro.2026.101282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。